SELLAS Presents SLS009 Preclinical Data in Pancreatic Cancer
NEW YORK — September 25, 2026 SELLAS Life Sciences Group presented new preclinical data for SLS009 (tambiciclib) in patient-derived...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
NEW YORK — September 25, 2026 SELLAS Life Sciences Group presented new preclinical data for SLS009 (tambiciclib) in patient-derived...
REDWOOD CITY, Calif. — September 14, 2026 Revolution Medicines, Inc. announced that the U.S. Food and Drug Administration (FDA)...
Melbourne, Australia – August 27, 2026 Propanc Biopharma announced new preclinical and early translational data for PRP in pancreatic...
Irving, Texas, United States, Aug 27, 2026 Caris Life Sciences has announced the publication of a study in npj...
MELBOURNE, Australia, August 6, 2026 Propanc Biopharma announced compelling preclinical and early translational findings for its lead investigational therapy...
Revolution Medicines, Redwood City, Calif., July 22, 2026 Revolution Medicines announced that the U.S. Food and Drug Administration (FDA)...
REDWOOD CITY, Calif., July 7, 2026 Revolution Medicines has announced a major regulatory milestone as the European Medicines Agency...
Ramat Gan, Israel, July 1, 2026 Can-Fite BioPharma Ltd. announced that its Phase 2a clinical study evaluating Namodenoson in...
BOSTON, June 17, 2026 Verastem Oncology announced positive updated safety and efficacy findings from the Phase 1b/2a RAMP 205...
BOSTON, June 16, 2026 Verastem Oncology announced that the first patient has been dosed in the TARGET-D 201 Phase...
